Gilead Sciences, Inc. et al v. Lupin Limited et al
| Gilead Sciences, Inc., Gilead Sciences Ireland UC, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company |
| Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd. and MSN Pharmaceuticals Inc. |
| 1:2023cv00508 |
| May 9, 2023 |
| US District Court for the District of Delaware |
| Maryellen Noreika |
| Patent - Abbreviated New Drug Application(ANDA) |
| 35 U.S.C. ยง 271 Patent Infringement |
| None |
Docket Report
RSS Track this Docket
This docket was last retrieved on May 22, 2023. A more recent docket listing may be available from PACER.
| Document Text |
|---|
Filing 8
[SEALED] SO ORDERED re (7 in 1:23-cv-00508-MN, 122 in 1:21-cv-01621-MN) Stipulation and Order to Consolidate (Set/Reset Scheduling Order Deadlines - Fact Discovery completed by 7/31/2023. Opening Expert Reports due by 8/10/2023. Rebuttal Expert Reports due by 10/5/2023. Reply Expert Reports due by 11/9/2023. Expert Discovery due by 12/22/2023. Daubert Motions due by 1/5/2024. A Pretrial Conference is set for 5/6/2024 at 04:30 PM in Courtroom 4A before Judge Maryellen Noreika. A 5-day Bench Trial is set for 5/13/2024 at 09:00 AM in Courtroom 4A before Judge Maryellen Noreika. Signed by Judge Maryellen Noreika on 5/22/2023. This order has been emailed to local counsel. (dlw)
|
| Case associated with lead case: Create association to 1:21-cv-01621-MN. (dlw) |
| Filing 7 [SEALED] STIPULATION and [Proposed] Order to Consolidate by Gilead Sciences Ireland UC, Gilead Sciences, Inc., Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company. (Tigan, Jeremy) Modified on 5/19/2023 (dlw). |
| Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (nms) |
| Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company filed by Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company. (mpb) |
| Filing 5 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Gilead Sciences Inc. for Gilead Sciences Ireland UC filed by Gilead Sciences Ireland UC, Gilead Sciences, Inc.. (mpb) |
| Filing 4 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: April 18, 2023. Date of Expiration of Patent: See Attached.Thirty Month Stay Deadline: 10/18/2025. (mpb) Modified on 5/17/2023 (dlw). |
| Filing 3 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,039,718 B2 ;10,786,518 B2. (mpb) |
| Filing 2 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mpb) |
| Filing 1 COMPLAINT filed against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., MSN Pharmaceuticals Inc. ( Filing fee $ 402, receipt number ADEDC-4132009.) - filed by Janssen Products, L.P., Gilead Sciences Ireland UC, Gilead Sciences, Inc., Janssen Sciences Ireland Unlimited Company. (Attachments: #1 Exhibit A-B, #2 Civil Cover Sheet)(mpb) |
| No Summons Issued. (mpb) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
